What is in vivo CRISPR and why does it matter?
In vivo CRISPR means editing a patient's genes directly inside their body, rather than removing cells, editing them in a lab, and infusing them back (which is called ex vivo). The appeal is huge: a single treatment could potentially cure genetic diseases by fixing the faulty gene at its source, without the need for complex cell manufacturing. The first FDA-approved CRISPR therapy, for sickle cell disease, is an ex vivo treatment [5]; in vivo approaches are further behind because they must overcome the extra challenge of safely delivering the gene-editing tools to the right cells inside a living person [2][3][7].
The first human evidence is promising, but very early
The most direct human data comes from a phase 1 trial of NTLA-2001 for transthyretin (TTR) amyloidosis, a life-threatening disease where misfolded protein builds up in nerves and the heart. In just six patients, a single infusion of the CRISPR therapy — delivered via lipid nanoparticles — reduced serum TTR protein by an average of 87% at the higher dose (0.3 mg/kg) after 28 days, with only mild side effects [4]. This is a landmark proof-of-concept, but it is a tiny, early-stage study with no long-term data yet. A separate study in non-human primates showed that a related CRISPR base-editing approach could knock down the cholesterol-regulating gene PCSK9 by about 90% in the liver, with stable reductions in LDL cholesterol of about 60% for at least 8 months after a single dose [6]. While not human data, this supports the idea that durable in vivo editing is achievable.
The biggest hurdle: delivery and safety
All the reviews here agree that safe, efficient delivery is the central bottleneck keeping in vivo CRISPR from routine use [2][3][7]. Adeno-associated virus (AAV) vectors are the most common delivery vehicle, but they have serious limitations: they can trigger immune reactions, cause liver toxicity at high doses, and carry a risk of the editing machinery integrating into the wrong part of the genome [2][7]. Newer approaches like lipid nanoparticles (used in the TTR trial) and virus-like particles may be safer, but they are still being refined [7]. Off-target edits — unintended changes to other genes — remain a key safety concern, and better tools to detect them are needed [1][3]. The field is actively working on these problems, but they are not solved.
What would it take to become routine?
For in vivo CRISPR to become a standard medical option, several things must happen. First, larger and longer clinical trials need to confirm that the early results are durable and safe over years, not just months [1][4]. Second, delivery systems must improve to target specific tissues (like the liver or brain) without affecting healthy cells [2][3]. Third, manufacturing and regulatory systems need to catch up — these therapies are biologically complex and expensive, and global standards for production and approval are still evolving [1]. The FDA has signaled it expects 10-20 new gene therapy approvals per year by 2025, but most of those will likely be ex vivo or viral-vector-based gene therapies, not in vivo CRISPR [1]. In short, in vivo CRISPR is a revolutionary idea with early proof in humans, but it is not yet ready for the clinic.
About These Sources
This answer is built on 7 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 7 in Q1 journals, collectively cited 2,507 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 83 papers retrieved from a database of over 500 million.
Sources used in this answer
Clinical gene technology in Australia: building on solid foundations
This 2022 review of gene therapy in Australia notes that over 900 investigational gene therapies are in clinical studies, but highlights unresolved questions about long-term safety, durability, and manufacturing complexity, especially for in vivo approaches using AAV vectors.
Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
This 2025 review identifies key challenges for in vivo CRISPR delivery using AAV vectors, including immunogenicity, liver toxicity at high doses, and risk of off-target mutagenesis, and discusses engineering strategies to improve efficiency and safety.
Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges
This 2024 review emphasizes that while in vivo CRISPR holds great therapeutic promise, achieving full clinical translation requires enhanced specificity to target defective cells while minimizing harm to healthy cells, and highlights ongoing preclinical and clinical trials.
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
In a phase 1 trial of 6 patients with hereditary TTR amyloidosis, a single dose of the in vivo CRISPR therapy NTLA-2001 reduced serum TTR protein by a mean of 87% at the higher dose (0.3 mg/kg) at day 28, with only mild adverse events.
Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy
This 2024 news article reports that the FDA approved the first CRISPR-based gene editing therapy (exa-cel, Casgevy) for sickle cell disease, which is an ex vivo treatment, marking a regulatory milestone for the technology.
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
In a non-human primate study, a single infusion of lipid nanoparticles carrying CRISPR base editors achieved near-complete knockdown of PCSK9 in the liver, with stable reductions in LDL cholesterol of about 60% for at least 8 months.
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges
This 2022 review summarizes that AAV vectors remain a common delivery system for in vivo CRISPR but have unsolved issues including immunogenicity, liver toxicity, and genotoxicity, and highlights newer transient delivery systems like lipid nanoparticles and virus-like particles as potential solutions.